AKP Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetLow leverage (debt-to-equity ~0.19) and sizable equity provide durable financial flexibility. This cushion supports continued investment in manufacturing, R&D, and opportunistic capital allocation while reducing refinancing risk and preserving optionality through economic cycles.
Sustained Gross Margin ExpansionA 14-point gross margin uplift driven by productivity, throughput improvements and mix is structurally meaningful. Higher baseline margins improve cash flow potential per unit sold, support reinvestment and resilience to pricing pressure, and indicate scalable manufacturing economics.
Commercial & International MomentumBroad-based growth across commercial and international channels diversifies revenue beyond OEM timing. Consistent product-level gains and expanding geography reduce concentration risk, enabling steadier top-line expansion and improving the durability of future cash generation.
Bears Say
Ongoing GAAP Losses / Negative ROEPersistent GAAP losses and negative returns on equity limit the company’s ability to compound shareholder value and constrain internal funding for growth. Until profitability and ROE sustainably turn positive, reliance on cash reserves or external funding could restrict strategic flexibility.
Hyalofast FDA UncertaintyFDA deficiency on a PMA creates material timeline and outcome risk for U.S. commercialization. Delayed or adverse decisions can defer expected revenue, increase development costs, and reduce the near-term contribution of a regenerative asset to long-term growth plans.
CINGAL CMC And Manufacturing BurdenMeeting drug-regulated CMC requirements demands capital, time and operational upgrades. These structural investments raise fixed costs, lengthen time-to-market and can compress margins while adding execution risk that affects the scalability of a key growth product.
Anika Therapeutics News
AKP FAQ
What was Anika Therapeutics’s price range in the past 12 months?
Currently, no data Available
What is Anika Therapeutics’s market cap?
Anika Therapeutics’s market cap is CHF208.69M.
When is Anika Therapeutics’s upcoming earnings report date?
Anika Therapeutics’s upcoming earnings report date is Oct 29, 2026 which is in 83 days.
How were Anika Therapeutics’s earnings last quarter?
Anika Therapeutics released its earnings results on Jul 29, 2026. The company reported CHF0.34 earnings per share for the quarter, beating the consensus estimate of -CHF0.065 by CHF0.405.
Is Anika Therapeutics overvalued?
According to Wall Street analysts Anika Therapeutics’s price is currently Undervalued.
Does Anika Therapeutics pay dividends?
Anika Therapeutics does not currently pay dividends.
What is Anika Therapeutics’s EPS estimate?
Anika Therapeutics’s EPS estimate is 0.19.
How many shares outstanding does Anika Therapeutics have?
Currently, no data Available
What happened to Anika Therapeutics’s price movement after its last earnings report?
Anika Therapeutics reported an EPS of CHF0.34 in its last earnings report, beating expectations of -CHF0.065. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Anika Therapeutics?
Currently, no hedge funds are holding shares in CH:AKP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Anika Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
CHF17.01 (― Upside)
CHF17.01 (― Upside)
Blogger Sentiment
Bullish
CH:AKP Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth CHF33.2K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-42.24%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-2.24%
Trailing 12-Months
Company Description
Anika Therapeutics
Anika Therapeutics, Inc. is a company dedicated to joint preservation, innovating and providing early intervention orthopedic care across the globe, including the United States and Europe. Their core focus areas include osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and advanced bone-preserving joint technologies. All of Anika's products are developed, manufactured, and commercialized utilizing their proprietary hyaluronic acid (HA) technology platform. Their comprehensive product lines feature an OA pain management family, which includes established treatments like Monovisc, Orthovisc, Cingal, and Hyvisc, all designed to alleviate discomfort from osteoarthritis. The company's joint preservation and restoration offerings are extensive, comprising approximately 150 bone-sparing joint technology products, alongside solutions for sports medicine soft tissue repair and orthopedic regenerative therapies. Furthermore, Anika leverages its HA expertise in a non-orthopedic product family, developing applications such as adhesion barriers, advanced wound care products, ophthalmic solutions, and ear, nose, and throat treatments. Anika Therapeutics, Inc. was established in 1983 and is based in Bedford, Massachusetts.
AKP Company Deck
AKP Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlights clear commercial momentum (record international and commercial channel revenue), strong operational improvements (mid-60s gross margins, capacity expansions), and meaningful profitability gains (highest adjusted EBITDA since 2020) that supported upward guidance revisions. Key risks include FDA review uncertainty for Hyalofast, required CMC work for CINGAL, OEM revenue/order timing variability, modest U.S. pricing headwinds, and near-term cash conversion timing. Overall, positive execution and raised guidance outweigh the regulatory and timing headwinds.View all CH:AKP earnings summaries